Table 2 Key design features of studies evaluating liver protection drugs
Study characteristics | Studies conducted in China (n = 77) | Studies conducted in other countries (n = 8) |
|---|---|---|
Length of follow up | Â | Â |
<1 month | 5 | 1 |
<6 months | 19 | 4 |
> or = 6 months | 31 | 3 |
Unclear | 22 | 0 |
Clearly prospective | Â | Â |
Prospective | 51 | 8 |
Retrospective | 18 | 0 |
Unclear | 8 | 0 |
Random allocation | Â | Â |
Clear | 3 | 1 |
No | 20 | 6 |
Quasi | 15 | 0 |
Unclear | 39 | 1 |
Comparisons | Â | Â |
Placebo | 0 | 2 |
Anti-TB drugs alone | 32 | 2 |
Alternative liver protection drug(s) | 42 | 4 |
No | 3 | Â |
Methods for monitoring adverse events stated | 0 | 6 |
Adverse events reported | 29 | 2 |